Ligand Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Travere Therapeutics (TVTX) Tops Q1 EPS by 115c
May 4, 2023 5:02 PM EDTTravere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.09), $1.15 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $44 million versus the consensus estimate of $50.6 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
... MoreLigand Pharma (LGND) Tops Q1 EPS by $1.42; Offers FY23 Guidance
May 4, 2023 4:56 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $2.28, $1.42 better than the analyst estimate of $0.86. Revenue for the quarter came in at $44 million versus the consensus estimate of $32 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.60-$4.75, versus the consensus of... More
